Previous Close | 40.07 |
1-Year Change | -41.67% |
6-Months Change | 4.73% |
3-Months Change | 15.51% |
Moving Avg (50d) | 43.58 |
Moving Avg (200d) | 45.984 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 2.68B |
Beta (3-Years) | 0.79 |
Revenue Growth (ttm) | % |
Net Profit Margin (ttm) | 0.42% |
Return On Assets (ttm) | 0.15% |
EPS (ttm) | -0.26 |
PE Ratio (ttm) | -154.12 |
Dividend Yield | % |
Asset Description: | QuidelOrtho Corporation |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-23 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
40.871 | 42.073 | 42.875 | 44.077 | 46.08 | 48.084 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Life Sciences Tools & Services |
Country: | United States |
QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide. On May 8, 2020 the U.S. Food and Drug Administration has issued the first emergency use authorization for a COVID-19 antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing... Wikipedia